Skip to main content

Table 1 Clinical variables of patients at entry to the study

From: Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic therapy

 

ESO (n = 50)

LAN (n = 50)

Age (yr, s.e.m.)*

65.0 (2.2)

62.7 (2.3)

Sex (%)

  

 Male

37 (74%)

34 (68%)

 Female

13 (26%)

16 (32%)

Locations of ulcer (%)

  

 Stomach

22 (44%)

18 (32%)

 Duodenum

28 (56%)

32 (68%)

Endoscopic findings (%)

  

 Spurting

6(12%)

4 (8%)

 Oozing

15 (30%)

18 (36%)

 NBVV

29 (58%)

28 (56%)

Gastric contents (%)

  

 Blood

14 (28%)

9 (18%)

 Coffee grounds

22 (44%)

20 (40%)

 Clear

14 (28%)

21 (42%)

Shock (%)

21 (42%)

18 (36%)

Medical comorbidity (%)

33 (66%)

30 (60%)

Ulcer size (cm, s.e.m.)

1.4 (0.2)

1.6 (0.2)

H. pylori infection (%)

26 (68.4%)

25 (68.6%)

Hemoglobin (g/dl, s.e.m.)

9.6(0.34)

10.7(0.38)

Rockall score (mean, s.e.m.)

5.3 (0.2)

5.3 (0.3)

  1. *Numerical variables expressed as mean and standard error of mean (s.e.m.)
  2. There were no statistically significant differences between the two groups.